- Research article
- Open Access
- Open Peer Review
Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models
© Gupta and Srivastava; licensee BioMed Central Ltd. 2012
- Received: 8 December 2011
- Accepted: 24 July 2012
- Published: 24 July 2012
HER2 is an oncogene, expression of which leads to poor prognosis in 30% of breast cancer patients. Although trastuzumab is apparently an effective therapy against HER2-positive tumors, its systemic toxicity and resistance in the majority of patients restricts its applicability. In this study we evaluated the effects of phenethyl isothiocyanate (PEITC) in HER2-positive breast cancer cells.
MDA-MB-231 and MCF-7 breast cancer cells stably transfected with HER2 (high HER2 (HH)) were used in this study. The effect of PEITC was evaluated using cytotoxicity and apoptosis assay in these syngeneic cells. Western blotting was used to delineate HER2 signaling. SCID/NOD mice were implanted with MDA-MB-231 (HH) xenografts.
Our results show that treatment of MDA-MB-231 and MCF-7 cells with varying concentrations of PEITC for 24 h extensively reduced the survival of the cells with a 50% inhibitory concentration (IC50) of 8 μM in MDA-MB-231 and 14 μM in MCF-7 cells. PEITC treatment substantially decreased the expression of HER2, epidermal growth factor receptor (EGFR) and phosphorylation of signal transducer and activator of transcription 3 (STAT3) at Tyr-705. The expression of BCL-2-associated × (BAX) and BIM proteins were increased, whereas the levels of B cell lymphoma-extra large (BCL-XL) and X-linked inhibitor of apoptosis protein (XIAP) were significantly decreased in both the cell lines in response to PEITC treatment. Substantial cleavage of caspase 3 and poly-ADP ribose polymerase (PARP) were associated with PEITC-mediated apoptosis in MDA-MB-231 and MCF-7 cells. Notably, transient silencing of HER2 decreased and overexpressing HER2 increased the effects of PEITC. Furthermore, reactive oxygen species (ROS) generation, mitochondrial depolarization and apoptosis by PEITC treatment were much higher in breast cancer cells expressing higher levels of HER2 (HH) as compared to parent cell lines. The IC50 of PEITC following 24 h of treatment was reduced remarkably to 5 μM in MDA-MB-231 (HH) and 4 μM in MCF-7 (HH) cells, stably overexpressing HER2. Oral administration of 12 μM PEITC significantly suppressed the growth of breast tumor xenografts in SCID/NOD mice. In agreement with our in vitro results, tumors from PEITC-treated mice demonstrated reduced HER2, EGFR and STAT3 expression and increased apoptosis as revealed by cleavage of caspase 3 and PARP. In addition our results show that PEITC can enhance the efficacy of doxorubicin.
Our results show a unique specificity of PEITC in inducing apoptosis in HER2-expressing tumor cells in vitro and in vivo and enhancing the effects of doxorubicin. This unique specificity of PEITC offers promise to a subset of breast cancer patients overexpressing HER2.
- in vivo
The HER2/neu protein belongs to the family of epidermal growth factor receptors (EGFRs) and is known to be amplified in several neoplasms such as breast, salivary gland, stomach, kidney and lung. It is overexpressed in about 30% of breast cancer patients [1–6]. The cytoplasmic domain of this intact tyrosine kinase receptor has been implied to generate normal mitogenic as well as transforming signals , indicating its direct role in cell proliferation . HER2 expression has been correlated with poor prognosis in cancer patients by mechanisms such as impaired DNA repair , angiogenesis  and metastasis . The oncogenic property of HER2 can be well enunciated, but its role in chemotherapy is not clearly elucidated because of its obscured molecular mechanisms. Though there are effective approaches for targeting HER2 such as trastuzumab (herceptin), which is a specific antibody for HER2, it is associated with toxicity and/or resistance. This implies a need for the search of better therapeutic agents that can target HER2-positive cancer cells.
Doxorubicin (Adriamycin) is used to treat patients in the early stages of breast cancer. The normal dosage of doxorubicin usually ranges 40 to 60 mg/m2. It is well established that a significant percentage of patients on doxorubicin therapy face a risk of cardiotoxocity at these doses . A lifetime cumulative dose of about 500 mg/m2 has been associated with chronic cardiotoxicity . To avoid the drawbacks of doxorubicin, it is important to find novel therapies that can reduce its dose without compromising its therapeutic effects. It has been shown that doxorubicin can downregulate EGFR but not HER2 . The approach of combination therapies can help to enhance its efficacy in HER2-positive patients.
Interestingly in two clinical studies, it was observed that HER2-positive tumors responded better to the chemotherapy regimen than HER2-negative tumors [15, 16]. Another study illustrated that cleavage of HER2 mediated apoptosis in cancer cells by inducing intrinsic apoptosis pathway . These studies indicated that the role of HER2 may be reciprocating between antiapoptotic and proapoptotic, but the conditions and agents that modulated this balance need to be identified. These studies also raised a question on the role of HER2 in cancer and provide rationale to study its possible dual role.
Various recent epidemiological studies have indicated that consumption of cruciferous vegetables such as garden cress, broccoli and so on, reduces the risk of breast cancer [18, 19]. The glucosinolate-derived phenethyl isothiocyanates (PEITC) present in these vegetables has promising antitumorigenic effects, as mentioned by various studies [19–23]. Clinical studies on PEITC for lung cancer are currently underway . These facts reinforce the importance and necessity of more preclinical studies required on this compound to expand and discover its true potential in breast cancer.
Our current studies establish the anticancer effects of PEITC in HER2-positive tumor cells. Our results show that the growth suppressive effects of PEITC in breast cancer cells were mediated by HER2 depletion in both in vitro and in vivo models and that HER2-expressing cells were more sensitive to PEITC-induced apoptosis. In addition, our study shows that in combination, PEITC can significantly enhance the apoptosis-inducing effects of doxorubicin. Our study provides a direction towards the mechanism of HER2-mediated sensitivity of cells to chemotherapy.
Human breast carcinoma cell lines MCF-7 and MDA-MB-231 were obtained from American Type Culture Collection (ATCC; http://www.atcc.org) and were maintained in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 5% penicillin/streptomycin/neomycin (PSN) and 0.01 mg/ml insulin and Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS and 5% PSN, respectively, unless otherwise stated. The HER2 overexpressing cells MDA-MB-231 (high HER2 (HH)) cells and their vector controls were kindly provided by Dr Patricia S Steeg (National Institutes of Health, Bethesda, MD, USA) and Dr Quentin Smith (Texas Tech University Health Sciences Center, Amarillo, TX, USA) and were maintained in DMEM supplemented with 10% FBS, 5% penicillin, streptomycin, neomycin solution and 300 μg/ml zeocin. HER2 was transfected in brain seeking subset of MDA-MB-231 cells. No significant difference was observed at molecular level in these cells and parental MDA-MB-231 cells. The MCF-7 overexpressing HER2 cells were kindly provided by Dr Huang Fei (Bristol-Myers Squibb Co., Princeton, NJ, USA) and were cultured in DMEM supplemented with 10% FBS and 5% PSN. The ATCC uses DNA fingerprinting (microsatellite analysis) for cell line authentication. All the cells used in this study were within 20 passages after receipt or resuscitation.
Cells were plated at a density of 2,000 to 5,000 cells/well in 96-well plates, allowed to attach overnight and treated with different concentrations of PEITC (molecular weight 163.2; purity > 99%; Sigma Aldrich, St. Louis, MO, USA) for various time intervals. The cells were fixed with ice cold 10% trichloroacetic acid, washed and stained with sulforhodamine B dye. The optical density was measured in Tris base solution using a plate reader after washing the dye with 1% acetic acid solution as described by us previously .
Annexin V-fluorescein isothiocyanate (FITC) apoptosis assay
The apoptosis assay was performed using a kit (BD Biosciences, San Jose, CA, USA) according to manufacturer's instructions. Approximately 0.3 × 106 cells were plated into six-well plates and left overnight for attachment. After treatment for 24 h with 0 to 15 μM PEITC, cells were harvested by trypsinization and suspended in phosphate-buffered saline (PBS) to a cell density of 1 × 106/ml. A total of 100 μl of binding buffer, 5.0 μl of Annexin V-FITC and 5 μl of propidium iodide were added to the suspension and incubated for additional 20 minutes at room temperature in the dark. Total sample volume was made up to 500 μl with binding buffer. Samples were incubated on ice in the dark and analyzed by flow cytometer after vortexing (Accuri C6, Ann Arbor, MI, USA).
Enzyme-linked immunosorbent assay (ELISA) apoptosis assay
Histone associated DNA fragmentation during apoptosis was analyzed using an ELISA kit (Roche Applied Science, Indianapolis, IN, USA). Approximately 1.0 × 104 cells were plated in each well in a 96 well plate and left overnight for attachment. After being treated with different concentrations of PEITC for 24 h, cells were processed according to the manufacturer's instructions and as described by us previously .
Hydrogen peroxide determination
Cells were plated in a six-well plate at a density of 0.3 × 106 cells per well and were allowed to attach overnight. After 24 h of treatment with PEITC, cells were harvested and lysed as described under western blotting analysis to collect and estimate the protein. The protein was transferred to 96 well plates at a concentration of 5 μg per well. The hydrogen peroxide (H2O2) content was determined using the Quantichrom (Bioassay Systems, Hayward, CA, USA) peroxide assay kit as per the manufacturer's instructions and described by us .
Mitochondrial membrane potential
Cells were plated at a density of 0.3 × 106 cells/well in a six-well plate, allowed to attach overnight and treated with 10 μM PEITC for 24 h. Prior to collection, cells were incubated with 100 nM tetramethylrhodamine (TMRM) (Life Technologies, Grand Island, NY, USA) for 20 minutes. Cells were washed with PBS, resuspended in fluorescence-activated cell sorting (FACS) running buffer and analyzed by flow cytometry (Accuri C6) as described by us .
Western blot analysis
The cells were treated with varying concentrations of PEITC (5, 10 and 15 μM) for 24 h. In a time-dependent study, cells were treated with 10 μM PEITC for 0, 1, 2, 4, 8, 12, 16, 24 and 48 h. In another experiment, MDA-MB-231 cells were treated with 10 mM Tiron for 1 h prior to treatment with 10 μM PEITC for 24 h. Whole cell lysates were prepared using 4% (w/v) CHAPS buffer (6 M urea, 2 M thiourea, 10 mM Tris pH 7.4) while tumor lysates were prepared by homogenizing the tumors in PBS. Control and treated protein was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the segregated protein was transferred on a polyvinylidene fluoride (PVDF) membrane. The membrane was developed as described by us previously using primary antibodies specific to human HER2 (Abcam, Cambridge, MA, USA; 1:700), EGFR (Cell Signaling, Danvers, MA, USA; 1:1000), phosphorylated signal transducer and activator of transcription 3 (p-STAT3) (Y705) (Cell Signaling, Danvers, MA, USA; 1:1000), STAT3 (Cell Signaling, Danvers, MA, USA; 1:1000), BIM (Cell Signaling, Danvers, MA, USA; 1:2000), BCL-2-associated × (BAX) (Cell Signaling, Danvers, MA, USA; 1:2000), B-cell lymphoma-extra large (BCL-XL) (Cell Signaling, Danvers, MA, USA; 1:1000), X-linked inhibitor of apoptosis protein (XIAP) (Cell Signaling, Danvers, MA, USA; 1:1000), cleaved caspase 3 (Cell Signaling, Danvers, MA, USA; 1:1000), cleaved poly-ADP ribose polymerase (PARP) (Cell Signaling, Danvers, MA, USA; 1:1000) and actin (Sigma Aldrich, St. Loius, MO, USA; 1:10,000) [28, 29].
Mitochondria-free cytosolic fractionation
The cell fractionation was performed using the mitochondrial extraction kit (Pierce, Rockford, IL, USA) as per the manufacturer's instructions. The cells were plated at density of 5 × 106 cells per 150 mm petri dish, left at incubation for attachment overnight and then treated with 10 μM PEITC for 24 h. Cells were harvested using trypsin after treatment and processed as per manufacturer's instructions.
HER2 silencing using HER2 small interfering (si)RNA
Approximately 0.3 × 106 cells were plated in a six-well plate and left overnight for attachment. The next day cells were transfected with HER2 siRNA or scrambled siRNA (Cell Signaling, Danvers, MA, USA) as per manufacturer's instructions using siPORT transfection reagent. After 2 days of transfection, cells were treated with 10 μM PEITC for 24 h, and the cell lysate was used for western blotting.
HER2 overexpression by transient transfection
HER2 plasmid with pcDNA3 vector backbone was obtained from Addgene. Approximately 0.3 × 106 cells per well were plated in six-well plates and left overnight for attachment. The next day cells were transfected with 5 μg HER2 plasmid using Xfect Transfection reagent (Clontech, Mountainview, CA, USA) as per manufacturer's instructions. After 2 days of transfection, cells were treated with 10 μM PEITC. After 24 h of treatment, cell lysate was analyzed by western blotting.
Sections of approximately 20 micron were obtained from snap frozen tumor tissues for tumor analysis. The sections were gently placed on positively charged slides, fixed using 4% paraformaldehyde and blocked with 5% goat serum for 60 minutes as described by us previously . For immunostaining cells were plated in a six-well plate on a coverslip at a density of 0.1 × 106 cells/well, allowed to attach overnight and treated with 10 μM PEITC for 24 h. Cells were rinsed twice with PBS for 5 minutes each, fixed with an ice cold mixture of acetone and methanol (1:1), rinsed with PBS and blocked with 5% goat serum for 60 minutes. Eventually, cells and tumor sections were probed with antibodies specific to HER2, p-STAT3 (Y705) and cleaved caspase 3 overnight at 4°C, followed by incubation with Alexa Fluor 488 (anti-mouse) and Alexa Fluor 594 (anti-rabbit) secondary antibodies for 1 h by gentle rocking at room temperature. After washing the cells with PBS three times, the nucleus was counterstained with DRAQ 5 (Axxora LLC, San Diego, CA, USA). Cells and tumor sections were photographed under microscope (Olympus Inc.) after coverslips were mounted on the slides.
Tumor therapy model
Female SCID/NOD mice (4 to 6 weeks old) were obtained from Charles River (Wilmington, MA, USA) and maintained under specific pathogen-free conditions. The use of SCID/NOD mice and their treatment was approved by the Institutional Animal Care and Use Committee (IACUC), Texas Tech University Health Sciences Center, and the experiments were conducted in strict compliance with the regulations. Mice were given antioxidant-free AIN-76A special diet (TestDiet, Richmond, IN, USA) 1 week before starting the experiment. Exponentially growing MDA-MB-231 (HH) cells were harvested, washed twice with PBS and resuspended in 1:1 PBS/matrigel at a density of 50 × 106 cells per ml. A suspension of 0.1 ml containing 5 × 106 cells was injected in the right flank subcutaneously in the recipient mouse. Tumor volumes were measured three times a week (Monday, Wednesday and Friday), and animal weights were taken twice a week (Monday and Friday) as described by us previously [26, 30]. The tumor volumes were calculated from tumor lengths and widths using the formula (length × (width)2/2) . When the tumors reached a size of about 150 mm3, mice were randomly segregated into two groups with ten mice in each group. Test group of mice received 12 μmol PEITC (81 mg/kg) in PBS by oral gavage every day until day 35, whereas control mice received vehicle alone. No obvious signs of toxicity or discomfort were observed in the mice orally gavaged over the time. Mice were killed on day 35 by CO2 overdose, and death was confirmed by cervical dislocation in accordance with IACUC guidelines. The tumors were removed aseptically from each mouse and were snap frozen in liquid-nitrogen after taking the tumor weights for western blot analysis and immunofluorescence analysis.
Combination of doxorubicin and PEITC
The effect of PEITC in combination with conventional chemotherapy agent doxorubicin (purity > 98%, Sigma Aldrich, St. Loius, MO, USA) was evaluated in MDA-MB-231 and MDA-MB-231 (HH) cells. In brief, cells were treated with 4 μM PEITC and 3 μM doxorubicin for 24 h and analyzed by sulforhodamine B cell survival assay and western blotting as described above.
The statistical calculations and analysis were performed using Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA). Results represent means ± SD or SEM of at least three independent experiments. Data was analyzed by Student's t test. Differences were considered statistically significant at P < 0.05.
PEITC inhibits the proliferation of breast cancer cells
PEITC causes induction of apoptosis
To gain further insight into the mechanism of the growth inhibitory effects of PEITC, MDA-MB-231 and MCF-7 cells were treated with different concentrations of PEITC for 24 h and analyzed for apoptosis using Annexin V assay. As shown in Figure 1C, PEITC treatment induced about fourfold apoptosis in MDA-MB-231 cells at concentration as low as 5 μM. However, 5 μM PEITC induced twofold apoptosis in MCF-7 cells (Figure 1D). To confirm these observations, apoptosis was also evaluated using a cell death detection ELISA kit. Consistent with our Annexin V apoptosis data, PEITC induced apoptosis in both MDA-MB-231 and MCF-7 cells in a concentration-dependent manner (Additional file 1, Figure S1A, B).
PEITC treatment depletes the HER2 level and induces the mitochondrial pathway of apoptosis
HER2 silencing blocks PEITC-induced apoptosis
Overexpression of HER2 enhanced PEITC-induced apoptosis
Next, we were interested to see if HER2 overexpression could enhance PEITC-mediated apoptosis. We transfected MCF-7 cells with HER2-expressing plasmid and treated the cells with PEITC. Using transient transfection, we were able to achieve approximately 2.5-fold overexpression of HER2 in these cells. MCF-7 cells were chosen for HER2 transfection, because MCF-7 cells were relatively resistant to the cytotoxic effects of PEITC (Figure 1A, B). As shown in Figure 4B, overexpression of HER2 led to more PARP cleavage by PEITC treatment. Furthermore, significantly more apoptosis was observed by PEITC treatment in MCF-7 cells overexpressing HER2, as measured by ELISA cell death detection assay, confirming our observation made by western blotting (Additional file 2, Figure S2B).
Effect of PEITC treatment in cells stably overexpressing HER2
To determine the effect of PEITC on HER2 responsive and proapoptotic proteins, HER2-overexpressing cells were treated with varying concentrations of PEITC for 24 h and evaluated by western blot. Consistent with MDA-MB-231 and MCF-7 parent cell lines data, PEITC treatment substantially reduced the expression of HER2, EGFR, STAT3 and phosphorylation of STAT3 in MDA-MB-231 (HH) cells overexpressing HER2 (Figure 5C). Proapoptotic proteins BIM, BAX and BID were highly activated by PEITC treatment, whereas antiapoptotic BCL-XL and XIAP were significantly downregulated (Figure 5C). Substantial cleavage of caspase 3 and PARP was also observed in MDA-MB-231 (HH) cells in response to PEITC treatment (Figure 5C). Notably, cleavage of caspase-3 and/or PARP was substantially more in MDA-MB-231 (HH) cells by PEITC treatment as compared to parental cells. Similar observations were made in MCF-7 (HH) cells overexpressing HER2 (Figure 6B). Next, we wanted to see whether the overexpression of HER2 would increase the cytotoxic potential of PEITC. Therefore a cell survival assay was performed in MDA-MB-231 (HH) and MCF-7 (HH) cells after treatment with PEITC. As shown in Figure 5D, PEITC treatment significantly reduced the survival of MDA-MB-231 (HH) cells with an IC50 of 5 μM and 2 μM after 24 h and 72 h of treatment respectively. When compared with parent MDA-MB-231 cells, the IC50 of PEITC was about 38% to 50% less in MDA-MB-231 (HH) cells. Similarly, PEITC treatment decreased the survival of MCF-7 (HH) cells with an IC50 of 4 μM and 3 μM respectively after 24 h and 72 h treatment (Figure 6C). The IC50 of PEITC in MCF-7 (HH) cells was decreased by 50% to 71% as compared to MCF-7 cells by PEITC treatment. Taken together, these results clearly indicated that HER2 makes breast cancer cells more sensitive to the growth suppressive effects of PEITC.
PEITC decreases mitochondrial membrane potential
Reactive oxygen species (ROS) induction by PEITC treatment
Depolarization of mitochondria leading to cell death is usually due to excessive generation of ROS in the cells. We therefore measured hydrogen peroxide concentration in the cells using a commercial kit. As shown in Figure 7B, hydrogen peroxide level was much higher in MDA-MB-231 (HH) cells as compared to MDA-MB-231 cells in response to PEITC treatment (Figure 7B). Similar observations were made in MCF-7 (HH) cells (Figure 7C). These results once again indicate that HER2 increased the ability of breast cancer cells to generate hydrogen peroxide in response to PEITC treatment leading to cell death. The next step was to determine whether ROS (hydrogen peroxide) were involved in the downregulation of HER2 and apoptosis by PEITC treatment. In order to prove this association, MDA-MB-231 cells were pretreated with 10 mM Tiron (a general antioxidant) for 1 h to block ROS followed by treatment with 10 μM PEITC for 24 h. As shown in Figure 7D, Tiron treatment considerably blocked the downregulation of HER2 by PEITC treatment. Tiron also substantially decreased the apoptosis induced by PEITC treatment as shown by reduced cleavage of caspase-3 (Figure 7D).
Tumor therapy model
PEITC enhances the effects of doxorubicin
Our results indicated that PEITC treatment considerably suppressed the viability of MCF-7 and MDA-MB-231 breast cancer cells. The reduced viability of these cells was associated with HER2/EGFR downregulation. In addition PEITC treatment reduced the expression and the phosphorylation of STAT3. Overexpressing HER2 using HER2 plasmid enhanced the cytotoxic potential of PEITC in these cells. However, silencing HER2 using siRNA blocked the apoptosis induced by PEITC treatment relative to the cells with constitutive levels of HER2. Stable overexpression of HER2 in these cells made the cells more sensitive to the cytotoxic effects of PEITC as indicated by reduced IC50 values. Furthermore, our results indicate that PEITC treatment induced hydrogen peroxide production in breast cancer cells leading to mitochondrial membrane depolarization. In line with hydrogen peroxide production and mitochondrial membrane depolarization, PEITC treatment resulted in the release of cytochrome c into the cytosol, leading to the activation of the caspase 3 cascade. Oral administration of PEITC significantly suppressed the growth of breast tumors in SCID/NOD mice. Tumors from PEITC mice demonstrated reduced expression of HER2, EGFR, STAT3, BCL-XL and XIAP, and increased cleavage of BIM, caspase 3 and PARP indicating apoptosis. To the best of our knowledge, our study for the first time implicated the probable role of HER2 in sensitizing breast cancer cells to PEITC-induced apoptosis in vitro and in vivo.
HER2 is a tyrosine kinase associated with poor prognosis in breast cancer . Substantial evidence indicates its direct role in tumor progression by promoting migration, invasion, antiapoptotic pathways  and drug resistance . Under normal conditions HER2 plays an important role in the development of mammary glands and lactation during parturition , while deregulation of HER2 leads to the development and progression of breast cancer . Since 1989 efforts have been made to develop therapeutics for HER2-positive breast tumors [39, 40]. Trastuzumab (herceptin), a US Food and Drug Administration (FDA)-approved monoclonal antibody against HER2, was apparently effective in the treatment of HER2-positive tumors [41, 42]. However, patients with HER2-positive tumors frequently present primary or secondary resistance to this agent . Also, a significant number of patients show moderate to severe toxicity with trastuzumab [44–46]. These detrimental side effects of current targeted therapies raise a need for newer and better therapeutic agents for targeting HER2. Our results show efficacy of PEITC towards HER2-expressing breast cancer cells. Notably, previous studies have shown that PEITC is not toxic to normal cells . Although induction of cell death has been shown by PEITC in MCF-7 cells , the effect of PEITC on HER2 has not been reported so far. To ascertain the specificity of PEITC for HER2, we tested the effect of PEITC in two prototype and syngeneic breast cancer cell lines MDA-MB-231, MDA-MB-231 (HH), MCF-7 and MCF-7 (HH), which have varying levels of HER2. Interestingly we observed increased sensitivity of the cells with higher levels of HER2 towards PEITC. Some previous studies have shown reduced efficiency of chemotherapeutic drugs due to HER2 overexpression .
HER2 functions through homodimerization and heterodimerization with other EGFR family receptors to activate further downstream effectors . Some studies indicate the role of STAT3 in EGFR signaling in various cancers [49, 50]. Our current study also indicated EGFR inhibition in breast cancer cells by PEITC treatment. Furthermore, inhibition of STAT3 expression and phosphorylation by PEITC treatment in our model indicated the inhibition of survival pathways in breast cancer cells. In agreement with our studies, PEITC has been shown to suppress STAT3 activation in prostate cancer cells . Silencing and overexpression of HER2 showed changes in STAT3 phosphorylation. Though there is no established correlation yet between HER2 and STAT3, our results indicated that HER2 might be regulating STAT3. Detailed studies are needed to further confirm and establish a relationship between HER2 and STAT3.
During the intrinsic mitochondrial death pathway, cytochrome c is released from the mitochondria into the cytosol due to a decrease in mitochondrial membrane potential . Mitochondrial membrane potential is compromised as a result of ROS generation. Our results show that PEITC treatment caused ROS generation and mitochondrial depolarization, resulting in the release of cytochrome c, hence activating caspase 3 mediated apoptosis in agreement with the outcome of other study . Antioxidant Tiron significantly blocked the decrease in HER2 expression and apoptosis by PEITC treatment suggesting the regulation of HER2 by ROS. A recent study suggested that certain genes that are upregulated in HER2 tumors were activated during oxidative stress . Interestingly, the extent of ROS generation and mitochondrial depolarization by PEITC was much higher in HER2 overexpressing cells as compared to parent cells. These observations suggest a link between ROS, HER2 and mitochondrial damage by PEITC in breast cancer cells. Nonetheless, further studies are needed to correlate HER2 and mitochondrial functions. A recent study indicated the involvement of mitochondrial STAT3 in inhibiting ROS production via mitochondrial electron transport chain (ETC) complex I . We also observed inhibition of mitochondrial STAT3 by PEITC treatment in breast cancer cells (data not shown). It was not clear at this point whether ROS generation by PEITC in our model was through the interaction of mitochondrial STAT3 with ETC complex I and needs further investigation. In our studies we also observed significant inhibition of XIAP by PEITC treatment. XIAP is a known inhibitor of apoptosis , and transmits survival signals in breast cancer cells . Second mitochondria-derived activator of caspases (Smac) is a known repressor of XIAP and is elevated during apoptosis. We did not observe any significant change in the expression of Smac by PEITC treatment indicating Smac-independent suppression of XIAP in our model.
Oral administration of 12 μmol PEITC significantly suppressed the growth of breast tumor in vivo. In a recent study oral administration of 10 μmol/kg PEITC in rats resulted in the peak plasma concentration of 9.2 ± 0.6 μM PEITC . Notably, the IC50 of PEITC in HER2 overexpressing cells in our model was less than 5 μM. These results indicate that the therapeutic concentration of PEITC can be achieved clinically in human patients.
Doxorubicin has been used for breast cancer treatment for a long time, but its use has been associated with dose-related acute and chronic toxicity in most of the patients. Several measures have been taken to reduce its toxicity, such as combining it with other chemotherapeutic agents to reduce its dose without compromising its efficacy. Interestingly, our results showed that the cytotoxic effects of doxorubicin can be enhanced by concomitant use of PEITC. Combination of doxorubicin with PEITC effectively suppressed HER2 and STAT3 phosphorylation in breast cancer cells, resulting in enhanced apoptosis as compared to individual treatments respectively. These observations have clinical relevance as our data suggests that the effect of doxorubicin at low doses can be increased by PEITC in HER2-expressing breast cancer cells, which show poor response to doxorubicin therapy in general. Detailed in vitro and in vivo studies are required to establish this association.
Taken together, our results indicated that (i) HER2 is a potential molecular target of PEITC in breast cancer cells in vitro and in vivo and (ii) PEITC has a potential to enhance the cytotoxic effects of doxorubicin. Our study suggests a unique specificity of PEITC towards HER2-overexpressing breast cancer cells, indicating that PEITC could be beneficial to a subset of patient population overexpressing HER2.
Our studies clearly indicate a unique specificity of PEITC towards HER2 overexpressing breast cancer cells, indicating that PEITC could be beneficial to a subset of patient population overexpressing HER2, alone or in combination with doxorubicin.
This work was supported in part by R01 grants CA106953 and CA129038 (to SKS) awarded by the National Cancer Institute, NIH. The kind gifts of HER2-overexpressing MDA-MB-231 (HH) cells by Dr Patricia S Steeg (National Cancer Institute, Bethesda, MD, USA) and Dr Quentin Smith (Texas Tech University Health Sciences Center, Amarillo, TX, USA), and MCF-7 overexpressing HER2 cells by Dr Huang Fei and Dr Karen Reeves (Bristol-Myers Squibb) are greatly appreciated.
- Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25: 5287-5312. 10.1200/JCO.2007.14.2364.View ArticlePubMedGoogle Scholar
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.View ArticlePubMedGoogle Scholar
- King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985, 229: 974-976. 10.1126/science.2992089.View ArticlePubMedGoogle Scholar
- Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986, 1: 765-767.View ArticlePubMedGoogle Scholar
- Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA. 1985, 82: 6497-6501. 10.1073/pnas.82.19.6497.View ArticlePubMedPubMed CentralGoogle Scholar
- Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K, Yamamoto T: Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986, 6: 955-958.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A: HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J. 1989, 8: 167-173.PubMedPubMed CentralGoogle Scholar
- Ekerljung L, Lindborg M, Gedda L, Frejd FY, Carlsson J, Lennartsson J: Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun. 2008, 377: 489-494. 10.1016/j.bbrc.2008.10.027.View ArticlePubMedGoogle Scholar
- Boone JJ, Bhosle J, Tilby MJ, Hartley JA, Hochhauser D: Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther. 2009, 8: 3015-3023. 10.1158/1535-7163.MCT-09-0219.View ArticlePubMedGoogle Scholar
- Kumar R, Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol. 2001, 28 (Suppl 16): 27-32.View ArticlePubMedGoogle Scholar
- Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS: Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67: 4190-4198. 10.1158/0008-5472.CAN-06-3316.View ArticlePubMedGoogle Scholar
- Doroshow JH: Doxorubicin-induced cardiac toxicity. New Engl J Med. 1991, 324: 843-845. 10.1056/NEJM199103213241210.View ArticlePubMedGoogle Scholar
- Shi Y, Moon M, Dawood S, McManus B, Liu PP: Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011, 36: 296-305. 10.1007/s00059-011-3470-3.View ArticlePubMedGoogle Scholar
- Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takanabe-Mori R, Nishi E, Hasegawa K, Kita T, Kimura T: Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010, 87: 656-664. 10.1093/cvr/cvq148.View ArticlePubMedPubMed CentralGoogle Scholar
- Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006, 354: 2103-2111. 10.1056/NEJMoa054504.View ArticlePubMedGoogle Scholar
- Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer and Leukemia Group B (CALGB) Investigators: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007, 357: 1496-1506. 10.1056/NEJMoa071167.View ArticlePubMedGoogle Scholar
- Strohecker AM, Yehiely F, Chen F, Cryns VL: Caspase cleavage of HER-2 releases a Bad-like cell death effector. J Biol Chem. 2008, 283: 18269-18282. 10.1074/jbc.M802156200.View ArticlePubMedPubMed CentralGoogle Scholar
- Boggs DA, Palmer JR, Wise LA, Spiegelman D, Stampfer MJ, Adams-Campbell LL, Rosenberg L: Fruit and vegetable intake in relation to risk of breast cancer in the Black Women's Health Study. Am J Epidemiol. 2010, 172: 1268-1279. 10.1093/aje/kwq293.View ArticlePubMedPubMed CentralGoogle Scholar
- Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG: Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004, 134: 1134-1138.PubMedGoogle Scholar
- Wattenberg LW: Inhibition of carcinogenesis by minor anutrient constituents of the diet. Proc Nutr Soc. 1990, 49: 173-183. 10.1079/PNS19900022.View ArticlePubMedGoogle Scholar
- Palmer S: Diet, nutrition, and cancer. Prog Food Nutr Sci. 1985, 9: 283-341.PubMedGoogle Scholar
- Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W: Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res. 2003, 63: 3980-3986.PubMedGoogle Scholar
- Wang X, Di Pasqua AJ, Govind S, McCracken E, Hong C, Mi L, Mao Y, Wu JY, Tomita Y, Woodrick JC, Fine RL, Chung FL: Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem.Google Scholar
- Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC: Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl. 1996, 26: 54-71.View ArticlePubMedGoogle Scholar
- Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK: The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol. 2011, 67: 481-487. 10.1007/s00280-010-1463-1.View ArticlePubMedGoogle Scholar
- Sahu RP, Srivastava SK: The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J Natl Cancer Inst. 2009, 101: 176-193. 10.1093/jnci/djn470.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang R, Humphreys I, Sahu RP, Shi Y, Srivastava SK: In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis. 2008, 13: 1465-1478. 10.1007/s10495-008-0278-6.View ArticlePubMedGoogle Scholar
- Sahu RP, Zhang R, Batra S, Shi Y, Srivastava SK: Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis. 2009, 30: 1744-1753. 10.1093/carcin/bgp157.View ArticlePubMedPubMed CentralGoogle Scholar
- Kandala PK, Srivastava SK: Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget. 2012, 3: 435-449.View ArticlePubMedPubMed CentralGoogle Scholar
- Boreddy SR, Pramanik KC, Srivastava SK: Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res. 2011, 17: 1784-1795. 10.1158/1078-0432.CCR-10-1891.View ArticlePubMedPubMed CentralGoogle Scholar
- Euhus DM, Hudd C, LaRegina MC, Johnson FE: Tumor measurement in the nude mouse. Journal of Surgical Oncology. 1986, 31: 229-234. 10.1002/jso.2930310402.View ArticlePubMedGoogle Scholar
- Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I: Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer. 2008, 8: 129-10.1186/1471-2407-8-129.View ArticlePubMedPubMed CentralGoogle Scholar
- Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J: Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008, 27: 4434-4445. 10.1038/onc.2008.84.View ArticlePubMedPubMed CentralGoogle Scholar
- Asada S, Choi Y, Yamada M, Wang SC, Hung MC, Qin J, Uesugi M: External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc Natl Acad Sci USA. 2002, 99: 12747-12752. 10.1073/pnas.202162199.View ArticlePubMedPubMed CentralGoogle Scholar
- Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001, 20: 2499-2513. 10.1038/sj.onc.1204349.View ArticlePubMedGoogle Scholar
- Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.View ArticlePubMedGoogle Scholar
- Jones FE, Stern DF: Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene. 1999, 18: 3481-3490. 10.1038/sj.onc.1202698.View ArticlePubMedGoogle Scholar
- Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994, 1198: 165-184.PubMedGoogle Scholar
- Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Ullrich A, Slamon D: Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 1991, 11: 117-127. 10.1007/BF00918679.View ArticlePubMedGoogle Scholar
- Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9: 1165-1172.View ArticlePubMedPubMed CentralGoogle Scholar
- Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999, 21: 309-318. 10.1016/S0149-2918(00)88288-0.View ArticlePubMedGoogle Scholar
- Graziano C: HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today. 1998, 12: 1, 14-16.Google Scholar
- Wilken JA, Maihle NJ: Primary trastuzumab resistance: new tricks for an old drug. Ann NY Acad Sci. 2010, 1210: 53-65. 10.1111/j.1749-6632.2010.05782.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Abulkhair O, El Melouk W: Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol. 2011, 4: 186-191. 10.1159/000326063.View ArticlePubMedPubMed CentralGoogle Scholar
- Tanz R, Mahfoud T, Bazine A, Khmamouch R, Bensouda Y, Ismaili N, Benjaafar N, El Gueddari BK, Ichou M, Errihani H: Cardiac safety of trastuzumab in adjuvant: a review across 53 observations [in French]. J Gynecol Obstet Biol Reprod (Paris). 2011, 40: 144-148. 10.1016/j.jgyn.2010.12.003.View ArticleGoogle Scholar
- Chien KR: Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol. 2000, 27 (Suppl 11): 9-14.PubMedGoogle Scholar
- Wu XJ, Hua X: Targeting ROS: selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound. Cancer Biol Ther. 2007, 6: 646-647. 10.4161/cbt.6.5.4092.View ArticlePubMedGoogle Scholar
- Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, Richardson M, Rigaill G, Parrini MC, Lucchesi C, Bellanger D, Stern MH, Dubois T, Sastre-Garau X, Delattre O, Vincent-Salomon A, Mechta-Grigoriou F: Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010, 2: 211-230. 10.1002/emmm.201000073.View ArticlePubMedPubMed CentralGoogle Scholar
- Takata S, Takigawa N, Segawa Y, Kubo T, Ohashi K, Kozuki T, Teramoto N, Yamashita M, Toyooka S, Tanimoto M, Kiura K: STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer. 2012, 75: 24-29. 10.1016/j.lungcan.2011.05.015.View ArticlePubMedGoogle Scholar
- Zhou W, Grandis JR, Wells A: STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer. 2006, 95: 164-171. 10.1038/sj.bjc.6603234.View ArticlePubMedPubMed CentralGoogle Scholar
- Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, Young CY: Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res. 2009, 53: 878-886. 10.1002/mnfr.200800253.View ArticlePubMedPubMed CentralGoogle Scholar
- La Piana G, Fransvea E, Marzulli D, Lofrumento NE: Mitochondrial membrane potential supported by exogenous cytochrome c oxidation mimics the early stages of apoptosis. Biochem Biophys Res Commun. 1998, 246: 556-561. 10.1006/bbrc.1998.8664.View ArticlePubMedGoogle Scholar
- Syed Alwi SS, Cavell BE, Donlevy A, Packham G: Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones.Google Scholar
- Szczepanek K, Chen Q, Larner AC, Lesnefsky EJ: Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion. 2012, 12: 180-189. 10.1016/j.mito.2011.08.011.View ArticlePubMedGoogle Scholar
- Deveraux QL, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997, 388: 300-304. 10.1038/40901.View ArticlePubMedGoogle Scholar
- Dubrez-Daloz L, Dupoux A, Cartier J: IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle. 2008, 7: 1036-1046. 10.4161/cc.7.8.5783.View ArticlePubMedGoogle Scholar
- Ji Y, Kuo Y, Morris ME: Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res. 2005, 22: 1658-1666. 10.1007/s11095-005-7097-z.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/80/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.